title: [New model of the optimal oral antiplatelet treatment in patients with the ST-segment elevation myocardial infarction in Poland - authors' reply].
authors.forename: Dariusz
authors.initials: D
authors.lastname: Dudek
authors.forename: Krzysztof J
authors.initials: KJ
authors.lastname: Filipiak
authors.forename: Janina
authors.initials: J
authors.lastname: Stępińska
authors.forename: Artur
authors.initials: A
authors.lastname: Dziewierz
authors.forename: Andrzej
authors.initials: A
authors.lastname: Budaj
authors.forename: Maciej
authors.initials: M
authors.lastname: Lesiak
authors.forename: Adam
authors.initials: A
authors.lastname: Witkowski
authors.forename: Wiktor
authors.initials: W
authors.lastname: Kuliczkowski
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Opolski
authors.forename: Waldemar
authors.initials: W
authors.lastname: Banasiak
mesh_terms: D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists